Details of the Drug

General Information of Drug (ID: DMYPMR8)

Drug Name
Batoclimab
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Phase 3 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
C98V9UMX3D
DrugBank ID
DB16104
TTD ID
DMWA10

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neonatal Fc receptor (FCGRT) TTKLPHO FCGRN_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05403541) A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG). U.S.National Institutes of Health.
2 Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023 Jan;30(1):195-203.